IL6 and chronic kidney disease: Following on from these results, an ongoing trial, ZEUS, will compare ziltivekimab with placebo in patients with chronic kidney disease and elevated hsCRP to determine if the anti-inflammatory approach of directly reducing circulating IL-6 reduces CV event rates [142].